Monitor for further NHS expansion phases beyond spring 2027 and potential revenue disclosures in upcoming quarterly filings. The national rollout provides a scalable proof-of-concept that could lead to additional UK or international contracts.
Price Chart
Executive Summary
Avricore Health announced that NHS England has confirmed the national expansion of the Barts Health pharmacy cholesterol testing programme, powered by its HealthTab platform. Approximately 100 pharmacies across England will begin offering seven-minute cholesterol checks this fall as part of a national NHS initiative, with the first phase running until spring 2027. This represents a significant commercial validation and potential revenue catalyst for Avricore, though no financial terms or revenue projections were disclosed.
Key Facts
- NHS England confirmed national expansion of the Barts Health pharmacy cholesterol testing programme powered by Avricore's HealthTab platform
- Approximately 100 pharmacies across England will begin offering seven-minute cholesterol checks this fall
- First national phase runs until spring 2027
- Prior pilot programme tested 2,493 patients across 61 community pharmacies between January 2025 and March 2026
- 19% of pilot patients identified as high risk of heart attack or stroke within next decade
- At least 88 patients subsequently began statin therapy
- National expansion has attracted major media attention including coverage in The Guardian
Financial Impact
No financial terms or revenue projections disclosed; commercial validation of HealthTab platform at national NHS level
Risk Factors
- Dependence on continued NHS programme decisions and partnership renewals
- No disclosed financial terms or revenue commitments from NHS England
- Execution risk in deploying to 100 pharmacies and maintaining quality standards at scale
- Forward-looking statements subject to regulatory and market risks
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001493152-26-046627 |
| Exhibit: ex1.htm | 0001493152-26-046627 |
| Document: 0001493152-26-046627-index-headers.html | 0001493152-26-046627 |
| Document: 0001493152-26-046627-index.html | 0001493152-26-046627 |
| Document: 0001493152-26-046627.txt | 0001493152-26-046627 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 9, 2026 17d ago | 6-K | $0.000800 $0.000800 | · 0.00% | ▲ +1.49% | $0.000800 (−0.00%) |
Jul 10, 2026 15w ago | 6-K | $0.0332 $0.0483 | ▲ +45.51% | ▲ +46.46% | $0.000800 (−97.59%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers